CDK2 and chronic myelogenous leukemia, BCR-ABL1 positive: Although BGG463 demonstrated superior efficacy in phenotypic plastic prostate cancer cell lines, it is shown that BGG463 can exhibit indirect inhibition of alternate kinase function not related to CDK2, particularly inhibition of T315I BCL-ABL autophosphorylation in murine models of chronic myeloid leukemia (ref. 52).